Hidden messages in protein blueprints: New mechanism for regulating the activity of stem cells discovered
Scientists from the German Cancer Research Center (DKFZ) and the Heidelberg Institute of Stem Cell Technology and Experimental Medicine (HI-STEM)* and the Max Planck Institute in Freiburg have identified a new control mechanism that enables stem cells to adapt their activity in emergency situations. For this purpose, the stem cells simultaneously modify the blueprints for hundreds of proteins encoded in the gene transcripts. In this way, they control the amount of protein produced and can also control the formation of certain proteinisoforms. If this mechanism is inactivated, stem cells lose their self-renewal potential and can no longer react adequately to danger signals or inflammation.
To enable blood stem cells to produce the required amount of mature blood cells under emergency conditions, they simultaneously modify the blueprints for hundreds of proteins encoded in the gene transcripts.
© Adobe Stock
Messenger RNA molecules (mRNAs), the transcripts of genes, serve as the blueprint for the construction of proteins. In all higher organisms, the cell attaches a long chain of adenine nucleotides, the so-called poly(A) tail, to the rear end of the transcripts in a process known as polyadenylation. The length and position of the chain varies from organism to organism and serves to stabilize the RNA molecule.
Different signaling motifs show the participating enzymes the site where the poly(A) chain is to be attached to the transcript. This does not always happen at the same site of the mRNA. The differential use of these sites is known as "alternative polyadenylation". This mechanism affects the length of the so-called 3'-untranslated end of the mRNA, a region that contains information beyond the protein sequence. This 3'-untranslated region is particularly important for stability, localisation and the efficiency with which the transcripts are translated into proteins. "Only recently it has been known that some cell types use this mechanism to control how much protein is produced per transcript and which isoform is to be expressed," says Pia Sommerkamp, the lead author of the study conducted by DKFZ and HI-STEM.
By applying a novel sequencing method, the scientists were able to identify numerous genes that are essential for stem cell development and are regulated via alternative polyadenylation during differentiation or in response to inflammation. These include the central metabolic enzyme glutaminase, which can be produced in two differently active isoforms. As the researchers found out, the activation of blood stem cells leads to a change from the less active to the highly active glutaminase isoform. This switch is coordinated by alternative polyadenylation.
"Only this isoform switch enables the stem cells to adapt all the necessary metabolic pathways according to their needs. This includes rapid increases in activity that are necessary in the case of infections or inflammations," explains Nina Cabezas-Wallscheid, who was co-supervisor of the study at the MPI in Freiburg. "With alternative polyadenylation, we have now discovered another control level with which stem cells regulate vital processes. We now want to investigate in more detail whether cancer stem cells also use this mechanism for their own purposes in leukaemias. We hope that this will provide us with new approaches for fighting the disease," explains Andreas Trumpp, Director of HI-STEM gGmbH at DKFZ and senior author of the study.
*The Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH) is a partnership between the DKFZ and the Dietmar Hopp Foundation
Pia Sommerkamp, Sandro Altamura, Simon Renders, Andreas Narr, Luisa Ladel, Petra Zeisberger, Paula Leonie Eiben, Malak Fawaz, Michael A. Rieger, Nina Cabezas-Wallscheid und Andreas Trumpp: Differential alternative polyadenylation landscapes mediate hematopoietic stem cell activation and regulate glutamin metabolism.
CELL Stem Cell 2020, DOI: https://dx.doi.org/10.1016/j.stem.2020.03.003
With more than 3,000 employees, the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) is Germany’s largest biomedical research institute. DKFZ scientists identify cancer risk factors, investigate how cancer progresses and develop new cancer prevention strategies. They are also developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to questions relating to cancer.
To transfer promising approaches from cancer research to the clinic and thus improve the prognosis of cancer patients, the DKFZ cooperates with excellent research institutions and university hospitals throughout Germany:
The DKFZ is 90 percent financed by the Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.
